Evidence map›Paper›PMID 32051147›Full record

Trial reportDiabetes2020

Novel Detection and Restorative Levodopa Treatment for Preclinical Diabetic Retinopathy.

Cara T Motz, Kyle C Chesler, Rachael S Allen, Katie L Bales, Lukas M Mees, Andrew J Feola, April Y Maa, Darin E Olson, Peter M Thule, P Michael Iuvone and 2 more

Abstract readRandomized Controlled Trial
In one paragraph

Trial report in Diabetes, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

42 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Dopamine: A New Player in the Pathogenesis of Diabetic Retinopathy?International journal of molecular sciences · 2024
    Review
  16. Article
  17. Article
  18. Resilience to diabetic retinopathy.Progress in retinal and eye research · 2024
    Review
  19. Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors.

Cara T MotzCenter for Visual and Neurocognitive Rehabilitation, Atlanta Veterans Affairs Medical Center, Decatur, GA.
Kyle C CheslerCenter for Visual and Neurocognitive Rehabilitation, Atlanta Veterans Affairs Medical Center, Decatur, GA.
Rachael S AllenCenter for Visual and Neurocognitive Rehabilitation, Atlanta Veterans Affairs Medical Center, Decatur, GA.
Katie L BalesCenter for Visual and Neurocognitive Rehabilitation, Atlanta Veterans Affairs Medical Center, Decatur, GA.
Lukas M MeesCenter for Visual and Neurocognitive Rehabilitation, Atlanta Veterans Affairs Medical Center, Decatur, GA.
Andrew J FeolaCenter for Visual and Neurocognitive Rehabilitation, Atlanta Veterans Affairs Medical Center, Decatur, GA.
April Y MaaCenter for Visual and Neurocognitive Rehabilitation, Atlanta Veterans Affairs Medical Center, Decatur, GA.
Darin E OlsonDivision of Endocrinology, Metabolism and Lipids, Emory University, Atlanta, GA.
Peter M ThuleDivision of Endocrinology, Metabolism and Lipids, Emory University, Atlanta, GA.
P Michael IuvoneDepartment of Ophthalmology, Emory University, Atlanta, GA.
Andrew M HendrickDepartment of Ophthalmology, Emory University, Atlanta, GA.
Machelle T PardueCenter for Visual and Neurocognitive Rehabilitation, Atlanta Veterans Affairs Medical Center, Decatur, GA machelle.pardue@bme.gatech.edu.ORCID 0000-0001-8738-6839

Funding

P30-Core Grant for Vision Research Core CP30EY006360 · NEI · EMORY UNIVERSITY · PI GEISERT, ELDON E · 1986 to 2025
$15.3M
Dopamine treatments for diabetic retinopathyI01RX002615 · VA · VETERANS HEALTH ADMINISTRATION · PI PARDUE, MACHELLE T. · 2018 to 2021
–
The Effect of Estrogen Deficiencies on Vision Loss in GlaucomaIK2RX002342 · VA · VETERANS HEALTH ADMINISTRATION · PI FEOLA, ANDREW J · 2018 to 2023
–
Neuroprotective strategies for retinopathy and cognition in diabetesIK2RX002928 · VA · VETERANS HEALTH ADMINISTRATION · PI ALLEN, RACHAEL STEWART · 2019 to 2023
–
RR&D Research Career Scientist Award ApplicationIK6RX003134 · VA · VETERANS HEALTH ADMINISTRATION · PI PARDUE, MACHELLE T. · 2019 to 2025
–
NEI NIH HHS P30 EY006360RRD VA I01 RX002615RRD VA IK2 RX002342RRD VA IK2 RX002928RRD VA IK6 RX003134
6 · The paper itself

Abstract

Diabetic retinopathy (DR) is diagnosed clinically by directly viewing retinal vascular changes during ophthalmoscopy or through fundus photographs. However, electroretinography (ERG) studies in humans and rodents have revealed that retinal dysfunction is demonstrable prior to the development of visible vascular defects. Specifically, delays in dark-adapted ERG oscillatory potential (OP) implicit times in response to dim-flash stimuli (<-1.8 log cd · s/m

Indexed as

AdultAgedCarbidopaDiabetic RetinopathyDrug CombinationsElectroretinographyFemaleHumansLevodopaMaleMiddle AgedCarbidopacarbidopa, levodopa drug combinationDrug CombinationsLevodopa

Identifiers

PMID32051147
PMCPMC7306127

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.